Literature DB >> 11864956

In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults.

Shigeru Fujimura1, Seiichi Kato, Takeshi Kawamura, Akira Watanabe.   

Abstract

Antibiotic resistance in Helicobacter pylori has been a growing problem with current treatment regimens. However, second-line therapy for cases with eradication failure remains to be established. The aim of this study was to evaluate (in vitro) the potential use of rifampicin for H. pylori eradication. The susceptibility of 52 H. pylori strains isolated from children and adults to amoxicillin, clarithromycin, metronidazole and rifampicin was determined. Forty H. pylori isolates susceptible to these antibiotics were investigated for in vitro inducement of resistance. All isolates were susceptible to rifampicin. None of the H. pylori isolates tested acquired rifampicin resistance during prolonged exposure in in vitro inducement experiments. It is suggested that rifampicin has stable activity against H. pylori.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11864956     DOI: 10.1093/jac/49.3.541

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

2.  Efficacy and tolerability of rifampicin-based rescue therapy for Helicobacter pylori eradication failure in peptic ulcer disease.

Authors:  Vineet Ahuja; Vikram Bhatia; S Dattagupta; Akshay Raizada; Mahesh Prakash Sharma
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

Review 3.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

4.  14C-urea breath test in patients undergoing anti-tuberculosis therapy.

Authors:  Sayed Amir Mirbagheri; Amir Ali Sohrabpour; Mehrdad Hasibi; Babak Moghimi; Mehdi Mohamadnejad
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

Review 5.  How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

Authors:  Enzo Ierardi; Floriana Giorgio; Giuseppe Losurdo; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

6.  Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates.

Authors:  Laure Brigitte Kouitcheu Mabeku; Bertrand Eyoum Bille; Cromwell Tepap Zemnou; Lionel Danny Tali Nguefack; Hubert Leundji
Journal:  BMC Infect Dis       Date:  2019-10-22       Impact factor: 3.090

7.  Cellular metabolic network analysis: discovering important reactions in Treponema pallidum.

Authors:  Xueying Chen; Min Zhao; Hong Qu
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

8.  Comparison between the two drug regimens of PPI+Amoxicillin+ Rifampicin and PPI+Amoxicillin+ Levofloxacin for the treatment of H. pylori infections resistant to the first line drug regimen among patients referred to Ilam clinics.

Authors:  Ghobad Abangah; Alireza Raughani; Parisa Asadollahi; Khairollah Asadollahi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.